Can buspirone (BuSpar) be used for white‑coat hypertension?

Buspirone Should NOT Be Used for White Coat Hypertension

Buspirone (BuSpar) is not indicated for white coat hypertension and should not be used for this condition. In fact, buspirone can paradoxically cause elevated blood pressure and has been reported to cause severe hypertension in some cases 1, 2.

Why Buspirone is Inappropriate

FDA-Approved Indication

Buspirone is an anxiolytic medication approved specifically for generalized anxiety disorder (GAD), not for blood pressure management 1. The FDA drug label explicitly warns that buspirone administration has been associated with elevated blood pressure, particularly when combined with MAOIs 1.

Evidence of Blood Pressure Effects

• A recent case report documented severe hypertension in a 55-year-old woman after buspirone initiation, with significantly elevated catecholamine levels that normalized only after discontinuation 2
• While some animal studies showed mixed effects on blood pressure 3, 4, human data demonstrates buspirone can cause small drops in systolic blood pressure but also increases sympathetic activity 5
• The cardiovascular effects are unpredictable and not therapeutic for hypertension management

Proper Management of White Coat Hypertension

Diagnosis First

White coat hypertension does NOT require pharmacologic treatment 6. The 2015 Canadian guidelines explicitly state: "The available evidence at present does not support pharmacologic treatment of subjects with white coat hypertension" 6.

Recommended Approach

1. Confirm the diagnosis using out-of-office blood pressure monitoring:

   • ABPM (ambulatory BP monitoring) is preferred 6
   • HBPM (home BP monitoring) is an acceptable alternative 7
   • White coat hypertension is diagnosed when office BP ≥140/90 mm Hg but out-of-office BP is <135/85 mm Hg (awake ABPM/HBPM) or <130/80 mm Hg (24-hour ABPM) 6

2. Implement lifestyle modifications only 8:

   • Weight reduction if overweight
   • Moderate salt restriction
   • Regular exercise
   • Smoking cessation
   • Correction of glucose and lipid abnormalities

3. Monitor periodically for progression:

   • Follow-up with ABPM or HBPM at 3-6 month intervals 7
   • White coat hypertension can progress to sustained hypertension in 1-5% of patients per year 9
   • Cardiovascular risk is similar to normotensive individuals when no other risk factors are present 6

When to Consider Treatment

Antihypertensive medication should only be considered if:

• White coat hypertension progresses to sustained hypertension on repeat monitoring
• Other cardiovascular risk factors are present
• Target organ damage develops

Important Caveat

Do not confuse white coat hypertension with white coat effect in treated patients. If someone is already on antihypertensive therapy with elevated office readings but controlled out-of-office readings, this represents a white coat effect, not true uncontrolled hypertension 7, 10.

Bottom Line

Using buspirone for white coat hypertension would be off-label, potentially harmful (given reports of drug-induced hypertension), and contradicts guideline recommendations that white coat hypertension should be managed with lifestyle modifications and monitoring—not pharmacologic treatment.